lomaira
Lumira - A New Approach to Obesity Treatment
Lumira contains the same active ingredient found in Razin but in a different dosage and with a distinct release mechanism. Lumira functions as a stimulant of the nervous system and also increases levels of leptin, a hormone that suppresses appetite and enhances satiety. Lumira is not yet registered in Israel and is available under special approval as part of a comprehensive weight-loss treatment plan that includes medical supervision and dietary adjustments.
- Age 18 and older.
- BMI of 30 or higher, classified as severe obesity.
- BMI of 27 or higher, classified as overweight, provided there’s at least one additional obesity-related risk factor, such as diabetes, high blood pressure, or elevated blood lipids.
How does Lomaira work?
Lumaira contains the active ingredient Phentermine. This molecule has effects similar to amphetamines and acts on the sympathetic nervous system. Specifically, it functions as a stimulant that promotes the release of the neurotransmitter norepinephrine in the brain. This process also leads to increased levels of the hormone leptin, which suppresses appetite and enhances feelings of fullness. Additionally, Phentermine is the active component in both Lumaira and the weight-loss medication Razin; the differences between these medications lie in their concentration, recommended dosages, and administration schedules.
What does the science say about Lomaira?
Lumaira’s effectiveness has been evaluated in randomized, double-blind, placebo-controlled clinical trials. These studies were short-term and found that the most significant weight loss occurred during the initial weeks of treatment.
The Multidisciplinary Approach to Obesity Treatment
The most effective method for weight loss through medication is a personalized treatment plan, supported and monitored by a multidisciplinary team of experts.
Various clinical studies \[4,5] conducted in recent years have shown that the most successful approach to weight loss combines individually tailored medications at adjustable dosages, including medication combinations, with medical supervision and ongoing nutritional follow-up by a clinical dietitian within a structured treatment framework. This process significantly improves patient adherence and supports long-term weight maintenance.
The Obesity Treatment Center offers a comprehensive multidisciplinary weight loss program combined with medication-based treatment. This program includes:
Combined Treatment
Personal Guidance
Diagnosis
Personal Follow-Up
Reducing Side Effects
Continuity of Care
Personally Guided Nutritional Program
Lifestyle Habits
טבלת קליקים וויגובי - כל המינונים
Wegovy 0.25mg
| Wegovy 0.25mg | |
| מינון | קליק |
| 0.006 | 1 |
| 0.013 | 2 |
| 0.02 | 3 |
| 0.027 | 4 |
| 0.033 | 5 |
| 0.04 | 6 |
| 0.047 | 7 |
| 0.054 | 8 |
| 0.06 | 9 |
| 0.067 | 10 |
| 0.074 | 11 |
| 0.081 | 12 |
| 0.087 | 13 |
| 0.094 | 14 |
| 0.1 | 15 |
| 0.108 | 16 |
| 0.114 | 17 |
| 0.121 | 18 |
| 0.128 | 19 |
| 0.135 | 20 |
| 0.141 | 21 |
| 0.148 | 22 |
| 0.155 | 23 |
| 0.168 | 24 |
| 0.168 | 25 |
| 0.175 | 26 |
| 0.182 | 27 |
| 0.189 | 28 |
| 0.195 | 29 |
| 0.202 | 30 |
| 0.209 | 31 |
| 0.216 | 32 |
| 0.222 | 33 |
| 0.229 | 34 |
| 0.236 | 35 |
| 0.243 | 36 |
| 0.25 | 37 |
Wegovy 0.5mg
| Wegovy 0.5mg | |
| מינון | קליק |
| 0.0135 | 1 |
| 0.027 | 2 |
| 0.0405 | 3 |
| 0.0541 | 4 |
| 0.0676 | 5 |
| 0.0811 | 6 |
| 0.0946 | 7 |
| 0.1081 | 8 |
| 0.1216 | 9 |
| 0.1351 | 10 |
| 0.1486 | 11 |
| 0.1622 | 12 |
| 0.1757 | 13 |
| 0.1892 | 14 |
| 0.2027 | 15 |
| 0.2162 | 16 |
| 0.2297 | 17 |
| 0.2432 | 18 |
| 0.2568 | 19 |
| 0.2703 | 20 |
| 0.2838 | 21 |
| 0.2973 | 22 |
| 0.3108 | 23 |
| 0.3243 | 24 |
| 0.3378 | 25 |
| 0.3514 | 26 |
| 0.3649 | 27 |
| 0.3784 | 28 |
| 0.391 | 29 |
| 0.405 | 30 |
| 0.418 | 31 |
| 0.432 | 32 |
| 0.445 | 33 |
| 0.459 | 34 |
| 0.472 | 35 |
| 0.486 | 36 |
| 0.5 | 37 |
Wegovy 1mg
| Wegovy 1mg | |
| מינון | קליק |
| 0.013 | 1 |
| 0.026 | 2 |
| 0.04 | 3 |
| 0.053 | 4 |
| 0.066 | 5 |
| 0.08 | 6 |
| 0.093 | 7 |
| 0.106 | 8 |
| 0.12 | 9 |
| 0.133 | 10 |
| 0.146 | 11 |
| 0.16 | 12 |
| 0.173 | 13 |
| 0.186 | 14 |
| 0.2 | 15 |
| 0.213 | 16 |
| 0.226 | 17 |
| 0.24 | 18 |
| 0.253 | 19 |
| 0.266 | 20 |
| 0.28 | 21 |
| 0.293 | 22 |
| 0.306 | 23 |
| 0.32 | 24 |
| 0.333 | 25 |
| 0.346 | 26 |
| 0.36 | 27 |
| 0.373 | 28 |
| 0.386 | 29 |
| 0.4 | 30 |
| 0.413 | 31 |
| 0.426 | 32 |
| 0.44 | 33 |
| 0.453 | 34 |
| 0.466 | 35 |
| 0.48 | 36 |
| 0.493 | 37 |
| 0.506 | 38 |
| 0.52 | 39 |
| 0.533 | 40 |
| 0.546 | 41 |
| 0.56 | 42 |
| 0.573 | 43 |
| 0.586 | 44 |
| 0.6 | 45 |
| 0.613 | 46 |
| 0.626 | 47 |
| 0.64 | 48 |
| 0.653 | 49 |
| 0.666 | 50 |
| 0.693 | 51 |
| 0.693 | 52 |
| 0.706 | 53 |
| 0.72 | 54 |
| 0.733 | 55 |
| 0.746 | 56 |
| 0.76 | 57 |
| 0.773 | 58 |
| 0.786 | 59 |
| 0.8 | 60 |
| 0.813 | 61 |
| 0.826 | 62 |
| 0.84 | 63 |
| 0.853 | 64 |
| 0.866 | 65 |
| 0.88 | 66 |
| 0.893 | 67 |
| 0.906 | 68 |
| 0.92 | 69 |
| 0.933 | 70 |
| 0.946 | 71 |
| 0.96 | 72 |
| 0.973 | 73 |
| 0.986 | 74 |
| 1 | 75 |
Wegovy 1.7mg
| Wegovy 1.7mg | |
| מינון | קליק |
| 0.022 | 1 |
| 0.045 | 2 |
| 0.068 | 3 |
| 0.09 | 4 |
| 0.113 | 5 |
| 0.136 | 6 |
| 0.158 | 7 |
| 0.181 | 8 |
| 0.204 | 9 |
| 0.226 | 10 |
| 0.249 | 11 |
| 0.272 | 12 |
| 0.294 | 13 |
| 0.317 | 14 |
| 0.34 | 15 |
| 0.362 | 16 |
| 0.385 | 17 |
| 0.408 | 18 |
| 0.43 | 19 |
| 0.453 | 20 |
| 0.476 | 21 |
| 0.498 | 22 |
| 0.521 | 23 |
| 0.544 | 24 |
| 0.566 | 25 |
| 0.589 | 26 |
| 0.612 | 27 |
| 0.634 | 28 |
| 0.657 | 29 |
| 0.68 | 30 |
| 0.702 | 31 |
| 0.725 | 32 |
| 0.748 | 33 |
| 0.77 | 34 |
| 0.793 | 35 |
| 0.816 | 36 |
| 0.838 | 37 |
| 0.861 | 38 |
| 0.884 | 39 |
| 0.906 | 40 |
| 0.929 | 41 |
| 0.952 | 42 |
| 0.974 | 43 |
| 0.997 | 44 |
| 1.02 | 45 |
| 1.04 | 46 |
| 1.065 | 47 |
| 1.088 | 48 |
| 1.11 | 49 |
| 1.133 | 50 |
| 1.156 | 51 |
| 1.178 | 52 |
| 1.201 | 53 |
| 1.224 | 54 |
| 1.246 | 55 |
| 1.269 | 56 |
| 1.292 | 57 |
| 1.314 | 58 |
| 1.337 | 59 |
| 1.36 | 60 |
| 1.382 | 61 |
| 1.405 | 62 |
| 1.428 | 63 |
| 1.45 | 64 |
| 1.473 | 65 |
| 1.496 | 66 |
| 1.518 | 67 |
| 1.541 | 68 |
| 1.564 | 69 |
| 1.586 | 70 |
| 1.609 | 71 |
| 1.632 | 72 |
| 1.654 | 73 |
| 1.677 | 74 |
| 1.7 | 75 |
Wegovy 2.4mg
| Wegovy 2.4mg | |
| מינון | קליק |
| 0.032 | 1 |
| 0.064 | 2 |
| 0.096 | 3 |
| 0.128 | 4 |
| 0.16 | 5 |
| 0.192 | 6 |
| 0.224 | 7 |
| 0.256 | 8 |
| 0.288 | 9 |
| 0.32 | 10 |
| 0.352 | 11 |
| 0.384 | 12 |
| 0.416 | 13 |
| 0.448 | 14 |
| 0.48 | 15 |
| 0.512 | 16 |
| 0.544 | 17 |
| 0.576 | 18 |
| 0.608 | 19 |
| 0.64 | 20 |
| 0.672 | 21 |
| 0.704 | 22 |
| 0.736 | 23 |
| 0.768 | 24 |
| 0.8 | 25 |
| 0.832 | 26 |
| 0.864 | 27 |
| 0.896 | 28 |
| 0.928 | 29 |
| 0.96 | 30 |
| 0.992 | 31 |
| 1.024 | 32 |
| 1.056 | 33 |
| 1.088 | 34 |
| 1.12 | 35 |
| 1.152 | 36 |
| 1.184 | 37 |
| 1.216 | 38 |
| 1.248 | 39 |
| 1.28 | 40 |
| 1.312 | 41 |
| 1.344 | 42 |
| 1.376 | 43 |
| 1.408 | 44 |
| 1.44 | 45 |
| 1.472 | 46 |
| 1.504 | 47 |
| 1.536 | 48 |
| 1.568 | 49 |
| 1.6 | 50 |
| 1.632 | 51 |
| 1.664 | 52 |
| 1.696 | 53 |
| 1.728 | 54 |
| 1.76 | 55 |
| 1.792 | 56 |
| 1.824 | 57 |
| 1.856 | 58 |
| 1.888 | 59 |
| 1.92 | 60 |
| 1.952 | 61 |
| 1.984 | 62 |
| 2.016 | 63 |
| 2.048 | 64 |
| 2.08 | 65 |
| 2.112 | 66 |
| 2.144 | 67 |
| 2.176 | 68 |
| 2.208 | 69 |
| 2.24 | 70 |
| 2.272 | 71 |
| 2.304 | 72 |
| 2.336 | 73 |
| 2.368 | 74 |
| 2.4 | 75 |
מונג'רו / מאונג'רו טבלת קליקים - מינונים
Mounjaro 2.5mg
| מונג’רו 2.5mg | |
| מינון | קליק |
| 0.0417 | 1 |
| 0.0833 | 2 |
| 0.125 | 3 |
| 0.1667 | 4 |
| 0.2083 | 5 |
| 0.25 | 6 |
| 0.2917 | 7 |
| 0.3333 | 8 |
| 0.375 | 9 |
| 0.4167 | 10 |
| 0.5 | 12 |
| 0.625 | 15 |
| 0.75 | 18 |
| 0.8333 | 20 |
| 1 | 24 |
| 1.25 | 30 |
| 1.5 | 36 |
| 1.6667 | 40 |
| 2 | 48 |
| 2.5 | 60 |
Mounjaro 5mg
| מונג’רו 5mg | |
| קליק | מינון |
| 1 | 0.0833 |
| 2 | 0.1667 |
| 3 | 0.25 |
| 4 | 0.3333 |
| 5 | 0.4167 |
| 6 | 0.5 |
| 7 | 0.5833 |
| 8 | 0.6667 |
| 9 | 0.75 |
| 10 | 0.8333 |
| 12 | 1 |
| 15 | 1.25 |
| 18 | 1.5 |
| 20 | 1.6667 |
| 24 | 2 |
| 30 | 2.5 |
| 36 | 3 |
| 40 | 3.3333 |
| 48 | 4 |
| 60 | 5 |
Mounjaro 15mg
| מונג’רו 15mg | |
| קליק | מינון |
| 1 | 0.25 |
| 2 | 0.5 |
| 3 | 0.75 |
| 4 | 1 |
| 5 | 1.25 |
| 6 | 1.5 |
| 7 | 1.75 |
| 8 | 2 |
| 9 | 2.25 |
| 10 | 2.5 |
| 12 | 3 |
| 15 | 3.75 |
| 18 | 4.5 |
| 20 | 5 |
| 24 | 6 |
| 30 | 7.5 |
| 36 | 9 |
| 40 | 10 |
| 48 | 12 |
| 60 | 15 |
Mounjaro 7.5mg
| מונג’רו 7.5mg | |
| קליק | מינון |
| 1 | 0.125 |
| 2 | 0.25 |
| 3 | 0.375 |
| 4 | 0.5 |
| 5 | 0.625 |
| 6 | 0.75 |
| 7 | 0.875 |
| 8 | 1 |
| 9 | 1.125 |
| 10 | 1.25 |
| 12 | 1.5 |
| 15 | 1.875 |
| 18 | 2.25 |
| 20 | 2.5 |
| 24 | 3 |
| 30 | 3.75 |
| 36 | 4.5 |
| 40 | 5 |
| 48 | 6 |
| 60 | 7.5 |
Mounjaro 10mg
| מונג’רו 10mg | |
| קליק | מינון |
| 1 | 0.1667 |
| 2 | 0.3333 |
| 3 | 0.5 |
| 4 | 0.6667 |
| 5 | 0.8333 |
| 6 | 1 |
| 7 | 1.1667 |
| 8 | 1.3333 |
| 9 | 1.5 |
| 10 | 1.6667 |
| 12 | 2 |
| 15 | 2.5 |
| 18 | 3 |
| 20 | 3.3333 |
| 24 | 4 |
| 30 | 5 |
| 36 | 6 |
| 40 | 6.6667 |
| 48 | 8 |
| 60 | 10 |
Mounjaro 12.5mg
| מונג’רו 12.5mg | |
| קליק | מינון |
| 1 | 0.2083 |
| 2 | 0.4167 |
| 3 | 0.625 |
| 4 | 0.8333 |
| 5 | 1.0417 |
| 6 | 1.25 |
| 7 | 1.4583 |
| 8 | 1.6667 |
| 9 | 1.875 |
| 10 | 2.0833 |
| 12 | 2.5 |
| 15 | 3.125 |
| 18 | 3.75 |
| 20 | 4.1667 |
| 24 | 5 |
| 30 | 6.25 |
| 36 | 7.5 |
| 40 | 8.3333 |
| 48 | 10 |
| 60 | 12.5 |
Frequently Asked Questions (FAQ)
At the beginning of treatment, your doctor will determine the weekly dosage of Lomaira.
Lumaira should be taken according to your doctor's instructions, based on the prescribed dosage.
As with any medication, Lumaira treatment may cause side effects, though most are mild and resolve within days to weeks. Common side effects include fever, nausea or vomiting, and abdominal cramps.
It's important to remember that your physician, especially if specializing in obesity treatment, can advise on how to significantly reduce or even prevent medication side effects. Real-time, dynamic adjustments to medication - including dosage modifications and monitoring interactions with other drugs - can improve patient adherence and significantly reduce treatment dropout rates.
Rare side effects may include primary pulmonary hypertension and heart valve disease, but these mainly occur when the active ingredient phentermine is combined with other appetite-suppressant medications.
Lumaira should not be used by individuals with glaucoma, hyperthyroidism, severe heart conditions (such as heart valve defects, heart murmurs, or certain arrhythmias), moderate to severe hypertension, pulmonary hypertension, or by patients currently taking MAO inhibitor antidepressants.
Lumaira has not yet been approved for use in Israel and is not included in the national health basket. However, the medication can be obtained by having your physician submit a Form 29 Gimel request to the Ministry of Health. If approved, Lumaira can then be purchased at pharmacies.
The information on this page does not replace medical consultation or serve as a basis for diagnosis. For detailed information regarding the medication, please refer to the patient information leaflet as approved by the Ministry of Health. For any additional questions, please consult your healthcare provider or pharmacist.